Journal
NATURE REVIEWS IMMUNOLOGY
Volume 7, Issue 5, Pages 340-352Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nri2000
Keywords
-
Categories
Funding
- NCI NIH HHS [R01CA96943] Funding Source: Medline
- NHLBI NIH HHS [R01HL66279, R01HL083072] Funding Source: Medline
- NIAID NIH HHS [01AI064343] Funding Source: Medline
Ask authors/readers for more resources
Allogeneic haematopoietic stem-cell transplantation (SCT) is a curative therapy for haematological malignancies and inherited disorders of blood cells, such as sickle-cell anaemia. Mature alpha beta T cells that are contained in the allografts reconstitute T-cell immunity and can eradicate malignant cells in the recipient. Unfortunately, these T cells recognize the recipient as 'non-self' and employ a wide range of immune mechanisms to attack recipient tissues in a process known as graft-versus-host disease (GVHD). The full therapeutic potential of allogeneic haematopoietic SCT will not be realized until approaches to minimize GVHD, while maintaining the positive contributions of donor T cells, are developed. This Review focuses on research in mouse models pursued to achieve this goal.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available